Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110)

BACKGROUND: Adequate pharmacokinetic and safety data in neonates are lacking for most antiretroviral agents. Raltegravir is a selective HIV-1 integrase strand transfer inhibitor (INSTI) available in a granule formulation suitable for use in neonates and young infants as prophylaxis or treatment of H...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Acquir Immune Defic Syndr
Päätekijät: Clarke, Diana F., Acosta, Edward P., Cababasay, Mae, Wang, Jiajia, Chain, Anne, Teppler, Hedy, Popson, Stephanie, Graham, Bobbie, Smith, Betsy, Hazra, Rohan, Calabrese, Kat, Bryson, Yvonne, Spector, Stephen A., Lommerse, Jos, Mirochnick, Mark
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7144886/
https://ncbi.nlm.nih.gov/pubmed/31913995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000002294
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia